CoChat

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth

Open access
Niu, Mengmeng, Xu, Jing, Liu, Yang, Li, Yuhuang, He, Tao, Ding, Liangping, He, Yajun, Yi, Yong, Li, Fengtian, Guo, Rongtian, Gao, Ya, Li, Rui, Li, Luping, Fu, Mengyuan, Hu, Qingyong, Luo, Yangkun, Zhang, Chunyan, Qin, Kewei, Yi, Jianqiao, Yu, Shuhan, Yang, Jian, Chen, Hu, Wang, Liang, Li, Zhonghan, Dong, Biao, Qi, Shiqian, Ouyang, Liang, Zhang, Yujun, Cao, Yang, Xiao, Zhi-Xiong Jim · 2021 · Nature Communications
Cited by 59

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Abnormal activation of epidermal growth factor receptor (EGFR) drives non-small cell lung cancer (NSCLC) development. EGFR mutations-mediated resistance to tyrosine-kinase inhibitors (TKIs) is a major hurdle for NSCLC treatment. Here, we show that F-box protein FBXL2 targets EGFR and EGFR TKI-resistant mutants for proteasome-mediated degradation, resulting in suppression of EGFR-driven NSCLC growth. Reduced FBXL2 expression is associated with poor clinical outcomes of NSCLC patients. Furthermore, we show that glucose-regulated protein 94 (Grp94) protects EGFR from degradation via blockage of FBXL2 binding to EGFR. Moreover, we have identified nebivolol, a clinically used small molecule inhibitor, that can upregulate FBXL2 expression to inhibit EGFR-driven NSCLC growth. Nebivolol in combination with osimertinib or Grp94-inhibitor-1 exhibits strong inhibitory effects on osimertinib-resistant NSCLC. Together, this study demonstrates that the FBXL2-Grp94-EGFR axis plays a critical role in NSCLC development and suggests that targeting FBXL2-Grp94 to destabilize EGFR may represent a putative therapeutic strategy for TKI-resistant NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-26222-x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 59

Metadata

Authors
Niu, M., Xu, J., Liu, Y., Li, Y., He, T., Ding, L., He, Y., Yi, Y., Li, F., Guo, R., Gao, Y., Li, R., Li, L., Fu, M., Hu, Q., Luo, Y., Zhang, C., Qin, K., Yi, J., Yu, S., Yang, J., Chen, H., Wang, L., Li, Z., Dong, B., Qi, S., Ouyang, L., Zhang, Y., Cao, Y., & Xiao, Z.-X. J.
Venue
Nature Communications
Published
2021-10-11
Volume
12
Issue
1
Pages
5919-5919
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3205685501
Cited by
59
References
9
FWCI
5.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. https://app.cochat.ai/papers/10.1038/s41467-021-26222-x
The paper
Niu, M., Xu, J., Liu, Y., Li, Y., He, T., Ding, L., He, Y., Yi, Y., Li, F., Guo, R., Gao, Y., Li, R., Li, L., Fu, M., Hu, Q., Luo, Y., Zhang, C., Qin, K., Yi, J., . . . Xiao, Z.-X. J. (2021). FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. Nature Communications. https://doi.org/10.1038/s41467-021-26222-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.